

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Stock news · updated daily
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center, and at-home settings Through a network serving more than 850,000 physicians and healthcare providers and more than 2,200 patient service centers, Labcorp is helping expand access to cervical cancer screening nationwide First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping MILFORD, Mass. and BURLINGTON, N.C.
WAT's AI Link launch and Anthropic collaboration aim to automate LC-MS workflows, streamline lab operations and drive instrument demand.
Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027 First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping Quest Diagnostics serves half of U.S. physicians and hospitals and one in three American adults each year MILFORD, Mass. and SECAUCUS, N.J.
Investors looking beyond artificial intelligence (AI) should closely watch two healthcare names – Thermo Fisher Scientific (TMO) and Waters (WAT) – according to Josh Brown. In his latest report, the Ritholtz' chief executive highlighted laboratory equipment suppliers whose improving businesses are attracting buyers as tech stocks face pressure.
Accelerates research and development by enabling AI-augmented workflows and automated lab-in-the-loop cycles, already a new and fast-growing source of demand for Waters' instruments and consumables Leverages Waters' unique ability to take an AI-directed experiment from the research bench into development and into Empower™ Software, carrying its audit trail as the molecule moves into downstream, regulated settings Joins Anthropic's Model Hardware Standard (MHS) research program designed to enable AI agents to operate Waters instrument hardware directly and autonomously, cutting instrument integration from weeks to hours Brings Anthropic's Model Context Protocol (MCP) to waters_connect™ Software, enabling scientists to direct Waters instruments through proprietary agents linked to large language models (LLMs), as well as Claude Science MILFORD, Mass., Oct. 13, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that it has launched Waters AI Link, a software capability that brings Anthropic's Model Context Protocol (MCP) to its informatics platform and has joined Anthropic's Model Hardware Standard (MHS) research program.
Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.
Shares of Waters Corporation (NYSE: WAT - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $454.54 and last traded at $444.9030, with a volume of 52745 shares changing hands. The stock had previously closed at $440.12. Wall Street Analysts Forecast Growth WAT has been the subject
MILFORD, Mass., Oct. 1, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q3 2026 financial results conference call on Tuesday, November 3, 2026, at 8:00 a.m.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | 3.01 | 3.05 | Beat 1.3% | $1.65B |
| May 5, 2026 | 2.31 | 2.70 | Beat 16.9% | $1.27B |
| Feb 9, 2026 | 4.51 | 4.53 | Beat 0.4% | $932.4M |
| Nov 4, 2025 | 3.21 | 3.40 | Beat 5.9% | $799.9M |
| Aug 4, 2025 | 2.94 | 2.95 | Beat 0.3% | $771.3M |
| May 6, 2025 | 2.22 | 2.25 | Beat 1.4% | $661.7M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 2, 2026 | 2026-10-02 17:11:01 | View |
| 4 | Oct 2, 2026 | 2026-10-02 17:08:46 | View |
| 3 | Aug 31, 2026 | 2026-08-31 18:09:29 | View |
| 8-K | Aug 21, 2026 | 2026-08-21 09:20:55 | View |
| 10-Q | Aug 11, 2026 | 2026-08-11 16:16:07 | View |
| 4 | Aug 7, 2026 | 2026-08-07 17:20:18 | View |
| 8-K | Aug 4, 2026 | 2026-08-04 06:10:22 | View |
| 4 | Jul 2, 2026 | 2026-07-02 16:27:20 | View |
| 4 | Jul 2, 2026 | 2026-07-02 16:24:42 | View |
| 4 | Jun 25, 2026 | 2026-06-25 17:25:43 | View |
Proxy statement (DEF 14A) disclosures
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Knight Heather | director | A-Award | 57 | — |
| Sep 30, 26 | Jiang Wei | director | A-Award | 57 | — |
| Aug 21, 26 | Wu Tong (Nmn) | officer | 0 | — | |
| Aug 6, 26 | Kuebler Christopher A | director | M-Exempt | 3,626 @ $136.43 | $494.7K |
| Aug 6, 26 | Kuebler Christopher A | director | S-Sale | 3,626 @ $397.94 | $1.44M |
| Aug 6, 26 | Kuebler Christopher A | director | M-Exempt | 3,626 @ $136.43 | $494.7K |
| Jun 30, 26 | Knight Heather | director | A-Award | 63 | — |
| Jun 30, 26 | Jiang Wei | director | A-Award | 67 | — |
Current price $452.04
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 13, 26 | TD Cowen | maintain | Buy | Buy |
| Oct 7, 26 | Barclays | maintain | Overweight | Overweight |
| Oct 1, 26 | Guggenheim | maintain | Buy | Buy |
| Sep 21, 26 | Goldman Sachs | maintain | Buy | Buy |
| Sep 9, 26 | UBS | upgrade | Neutral | Buy |
| Aug 27, 26 | Piper Sandler | upgrade | Neutral | Overweight |
| Aug 10, 26 | Citigroup | maintain | Buy | Buy |
| Aug 5, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 5, 26 | TD Cowen | upgrade | Hold | Buy |
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 61.36 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 80.32 | Oscillator | Sell |
| Williams %R (14) | -31.03 | Oscillator | Neutral |
| MACD (12, 26, 9) | 7.76 (Hist 1.24) | Oscillator | Strong Buy |
| Average Directional Index (14) | 31.94 (+DI 26.5 / -DI 10.8) | Trend | Strong Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | WAT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 112.4x | 32.4x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 31.0x | EPS est. 14.58 | Discount |
| Price / Book | 2.9x | 28.2x | Discount |
| Price / Sales | 9.6x | 7.3x | Elevated |
| EV / EBITDA | 51.6x | 22.6x | Elevated |
| Return on equity | 1.9% | — | Weak |
| Gross margin | 50.8% | 58.7% | In line |
| Debt / Equity | 0.35 | 2.26 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 3.71 | Safe zone |
Discounted cash flow model
FY2025 · 10-K disclosure
| EMA 20 | 438.54 | MA | Strong Buy |
| SMA 20 | 438.63 | MA | Buy |
| EMA 50 | 423.95 | MA | Strong Buy |
| SMA 50 | 424.10 | MA | Strong Buy |
| SMA 200 | 367.66 | MA | Strong Buy |
FY2025 · 10-K disclosure